3.4Impact Factor
4.9CiteScore
22 daysTime to First Decision

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 26, Issue 3

June 2019 - 33 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (33)

Select all

Article

7 Citations

1,720 Views

4 Pages

Framing of the Opioid Problem in Cancer Pain Management in Canada

R. Asthana,
S. Goodall,
J. Lau,
C. Zimmermann,
P. L. Diaz,
A. B. Wan,
E. Chow and
C. De Angelis

Curr. Oncol.2019, 26(3), 410-413;https://doi.org/10.3747/co.26.4517

1 June 2019

Two guidelines about opioid use in chronic pain management were published in 2017: the Canadian Guideline for Opioids for Chronic Non-Cancer Pain and the European Pain Federation position paper on appropriate opioid use in chronic pain management. Th...

Full Article

Short Communication

19 Citations

2,667 Views

4 Pages

Gaps and Delays in Survivorship Care in the Return-to-Work Pathway for Survivors of Breast Cancer—A Qualitative Study

K. Bilodeau,
D. Tremblay and
M. J. Durand

Curr. Oncol.2019, 26(3), 414-417;https://doi.org/10.3747/co.26.4787

1 June 2019

Introduction: The number of survivors of breast cancer (bca) in Canada has steadily increased thanks to major advances in cancer care. But the resulting clientele face new challenges related to survivorship. The lack of continuity of care and the sid...

Full Article

Case Report

33 Citations

1,713 Views

4 Pages

Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab

S. D. Saibil,
L. Bonilla,
H. Majeed,
V. Sotov,
D. Hogg,
M. A. Chappell,
M. Cybulsky and
M. O. Butler

Curr. Oncol.2019, 26(3), 418-421;https://doi.org/10.3747/co.26.4381

1 June 2019

Combination immune checkpoint blockade with concurrent administration of the anti-CTLA4 antibody ipilimumab and the anti–PD-1 antibody nivolumab has demonstrated impressive responses in patients with advanced melanoma and other diseases. That combina...

Full Article

of 4

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Curr. Oncol. - ISSN 1718-7729

Imprint

Download Flyer